Hemoglobin crosfumarilAlternative Names: DCLHb; Diaspirin crosslinked haemoglobin; Haemoglobin crosfumaril; HemAssist; Human haemoglobin - Baxter
Latest Information Update: 10 Jul 2002
At a glance
- Originator Baxter Healthcare Corporation
- Mechanism of Action Oxygen carriers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Septic shock
- Discontinued Hypovolaemia; Shock; Stroke; Vascular disorders